Rosuvastatin and Ezetimibe

ApprovedSmall molecule

Rosuvastatin and Ezetimibe is one of 105 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

104

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular DiseaseActive, not recruiting

ImmunodeficiencyActive, not recruiting

HypertensionActive, not recruiting

Cardiovascular DiseaseApproved

Active, not recruiting

ImmunodeficiencyPhase 3

Active, not recruiting

HypertensionPhase 3

Active, not recruiting

Competition

Competitive Landscape

566 competitors in Hypertension

#DrugCompanyPhaseTrials

Rosuvastatin and Ezetimibe

Hanmi Pharmaceutical Company Limited

Approved

1 2

Zebeta

Teva

Preclinical

6 3

Edarbi

Takeda

Preclinical

4 4

Aceon

Institut de Recherches Internationales Servier

Preclinical

5 5

Winrevair

Merck & Co.

Preclinical

—6

Deltavit

HHyundai Pharmaceutical Co., LTD.

Preclinical

2 7

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 8

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

1 9

Disalcid

JJoslin Diabetes Center

Preclinical

1 10

Vivarin

HHikma Pharmaceuticals LLC

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Immunodeficiency

NCT06317051

Clinical

Trials by Indication[1]

Immunodeficiency1 trial

Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)

Active, not recruiting·KKirby Institute·Phase 3·NCT06317051·300 enrolled

Cardiovascular Disease1 trial

Effects of Statin for Elderly Patients With Atherosclerotic Cardiovascular Disease

Completed·KKorea University Anam Hospital·Phase 4·NCT04826354·582 enrolled

Hypertension1 trial

A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia

Completed· Hanmi Pharmaceutical Company Limited logo

Hanmi Pharmaceutical Company Limited·Phase 3·NCT04074551·145 enrolled

Statin1 trial

Compare the Pharmacokinetics of NVP-1205 and Coadministration of Rosuvastatin and Ezetimibe

Completed·NNVP Healthcare·Phase 1·NCT02029625·41 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Rosuvastatin and Ezetimibe. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rosuvastatin and Ezetimibe compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rosuvastatin and Ezetimibe. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hanmi Pharmaceutical Company Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Hanmi Pharmaceutical Company Limited

Rosuvastatin and Ezetimibe

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Immunodeficiency1 trial

Cardiovascular Disease1 trial

Hypertension1 trial

Statin1 trial

References

Drug Info

Quick Facts

Related News